AMLX News | Roxom Stocks

1 BTC

- USD

Loading market data...

Mkt Cap

$3.31B

Volume

926.08K

Next Earnings

November 5th

Mkt Cap

$3.47B

Volume

926.08K

Next Earnings

November 5th

Chart Financials Earnings News About Insider Filings

Is GLP-1 Stock Amylyx Still a Buy After Skyrocketing 247%?Amylyx Pharmaceuticals has surged 247% in 2026 following positive Phase 3 trial results for avexitide, its experimental treatment for post-bariatric hypoglycemia. With no current FDA-approved treatments for PBH and potential peak sales of $1.5 billion, the stock shows promise but may have already priced in much of the upside. The analyst suggests waiting for a pullback to $28-$30 per share for a better entry point.The Motley Fool · Sep 1, 2026

Global Amyotrophic Lateral Sclerosis Therapeutics Market Size/Share Worth USD 1964 Million by 2035 at 11.5% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)The global ALS therapeutics market is valued at USD 812 million in 2024 and is projected to reach USD 1,964 million by 2035, growing at an 11.5% CAGR. Growth is driven by innovations in genetic therapies, gene-silencing technologies, improved diagnostics, and increased disease awareness. Key players include Biogen, Ionis Pharmaceuticals, Amylyx Pharmaceuticals, and others developing disease-modifying treatments.GlobeNewswire Inc. · Feb 19, 2026

Antisense Oligonucleotide Therapeutics Clinical Trial Pipeline Appears Robust With 70+ Key Pharma Companies Actively Working in the Domain | DelveInsightAntisense oligonucleotide (ASO) therapeutics are emerging as a promising treatment approach for rare genetic and neuromuscular disorders, with over 70 pharmaceutical companies actively developing 90+ pipeline therapeutics targeting specific genetic mechanisms.GlobeNewswire Inc. · Aug 28, 2025

AMYLYX ALERT: Bragar Eagel & Squire, P.C. is Investigating Amylyx Pharmaceuticals, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the FirmLaw firm investigating potential claims against Amylyx Pharmaceuticals regarding allegedly misleading statements about Relyvrio drug launch and patient demand during November 2022 to November 2023 period.GlobeNewswire Inc. · Jul 14, 2025

Why Amylyx Pharmaceuticals Stock Was So Healthy This WeekAmylyx Pharmaceuticals' stock rose over 10% this week after the company reported positive results from a phase 2 clinical trial of its drug AMX0035 for the rare genetic disorder Wolfram Syndrome. The treatment was well-tolerated and showed sustained improvement in pancreatic function, leading the company to plan discussions with the FDA about advancing the drug to phase 3 testing.The Motley Fool · Oct 18, 2024

Breaking Down Amylyx Pharma: 9 Analysts Share Their ViewsAmylyx Pharma (NASDAQ:AMLX) underwent analysis by 9 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 6 0 3 0 0 Last 30D 1 0 0 0 0 1M Ago 1 0 1 0 0 2M Ago 3 0 2 0 0 3M Ago 1 0 0 0 0 Insights from analysts' 12-month price targets are revealed, presenting an average target of $9.22, a high estimate of $32.00, and a low estimate of $3.00. Highlighting a 66.73% decrease, the current average has fallen from the previous average price target of $27.71. Interpreting Analyst Ratings: A Closer Look A comprehensive examination of how financial experts perceive Amylyx Pharma is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target Andrew Fein HC Wainwright & Co. Maintains Buy $8.00 - Joel Beatty Baird Lowers Neutral $3.00 $4.00 Andrew Fein HC Wainwright & Co. Maintains Buy $8.00 - Andrew Fein HC Wainwright & Co. Maintains Buy $8.00 $8.00 Andrew Fein HC Wainwright & Co. Lowers Buy $8.00 $42.00 Neena Bitritto-Garg Deutsche Bank Lowers Buy $8.00 $36.00 Chris Shibutani Goldman Sachs Lowers Neutral $4.00 $40.00 Joel Beatty Baird Lowers Neutral $4.00 $37.00 Graig Suvannavejh Mizuho Raises Buy $32.00 $27.00 Key Insights: Action Taken: Responding to changing market ...Full story available on Benzinga.comBenzinga · May 10, 2024

Amylyx Pharmaceuticals, Inc. (AMLX) Reports Q1 Loss, Lags Revenue EstimatesAmylyx Pharmaceuticals (AMLX) delivered earnings and revenue surprises of -291.67% and 21.74%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?Zacks Investment Research · May 9, 2024

The Zacks Analyst Blog Highlights Bristol Myers, Moderna, 2seventy bio, Amylyx Pharmaceuticals and Syros PharmaceuticalsBristol Myers, Moderna, 2seventy bio, Amylyx Pharmaceuticals and Syros Pharmaceuticals are part of the Zacks top Analyst Blog.Zacks Investment Research · Apr 12, 2024

Biotech Stock Roundup: MRNA Up on Vaccine Data, BMY's Updates & More NewsModerna (MRNA) and Bristol Myers (BMY) are in focus on pipeline and regulatory updates.Zacks Investment Research · Apr 10, 2024

AMLXAmylyx Pharmaceuticals, Inc. Common Stock

AMLX

Pay with—

Start Trading

Available Balance0.00

Your PositionYou don't own any AMLX yet.

Related Tickers

Earnings

Mkt Cap

$3.31B

Volume

926.08K

Next Earnings

November 5th